Tests guide

MRI Contrast (Gadolinium)

Many MRI exams use a contrast agent, most often a gadolinium-based contrast agent (GBCA), to help certain tissues and blood vessels show up more clearly. This guide gives general information about what it is and how it is used.

Last updated 3 sources

At a Glance

  • MRI contrast agents usually contain gadolinium, a metal bound to a carrier molecule so it can be used safely in the body.
  • The contrast is typically injected into a vein through an IV line during the scan.
  • It can highlight areas with increased blood flow or inflammation and help show blood vessels.
  • Most people have no reaction or only mild, short-lived effects; serious allergic-type reactions are rare.
  • The FDA has noted that small amounts of gadolinium can remain in the body, including the brain, for months to years.
  • Kidney function is often considered because the kidneys remove most gadolinium from the body.

What It Is

Gadolinium is a rare earth metal with magnetic properties that change how nearby tissues appear on MRI. On its own, free gadolinium would be toxic, so in contrast agents it is tightly bound to another molecule (a chelate) that allows it to circulate and then be filtered out, mainly by the kidneys.

When given into a vein, the contrast travels through the bloodstream. Tissues with more blood supply, or areas where the normal barriers are disrupted, take up more contrast and often appear brighter on certain image types. Radiologists call this "enhancement."

Several different GBCAs are approved by the FDA. They differ in their chemical structure, which affects how stable they are and how much gadolinium may be retained. Not every MRI needs contrast; the decision depends on the clinical question.

Common Terminology

GBCA
Gadolinium-based contrast agent; the most common type of contrast used in MRI.
Enhancement
A term in MRI reports meaning a tissue became brighter after contrast was given.
Linear and macrocyclic agents
Two broad structural groups of GBCAs. Macrocyclic agents hold gadolinium more tightly and are associated with less retention in the body.
Gadolinium retention
Small amounts of gadolinium remaining in tissues such as brain, bone, and skin after an MRI with contrast.
Nephrogenic systemic fibrosis (NSF)
A rare but serious condition causing thickening of skin and other tissues, linked to certain GBCAs in people with severe kidney disease.
eGFR
Estimated glomerular filtration rate, a blood-test-based estimate of kidney function that may be checked before contrast.

Why the Test Is Done

Contrast may be used when clinicians want more detail than a non-contrast MRI can provide. Examples include:

  • Evaluating tumors or masses and how they relate to surrounding tissue.
  • Looking for areas of inflammation or infection.
  • Assessing certain conditions of the brain and spinal cord, such as multiple sclerosis activity.
  • Imaging blood vessels with MR angiography (MRA), although some MRA techniques do not need contrast.
  • Characterizing findings in organs such as the liver, kidneys, breast, or prostate.

What the Results Generally Describe

In a contrast MRI report, radiologists commonly describe:

  • Whether an area shows enhancement and, if so, its pattern, such as uniform, patchy, or rim-like.
  • How images before and after contrast compare.
  • The timing of enhancement in some exams, such as how quickly a tissue brightens and fades.
  • The type of contrast agent used, which is often listed in the technique section.
  • These descriptions are interpreted by a radiologist and the ordering clinician; enhancement alone does not mean any specific diagnosis.

How the Test Is Done

In general, contrast is given as follows:

  • A small IV catheter is placed in a vein, usually in the arm or hand.
  • Some images are typically taken before the contrast is given.
  • The contrast is injected by hand or by an automatic injector while the person stays in the scanner.
  • More images are taken after the injection; some people feel a brief cool sensation at the IV site.
  • The IV is removed after the exam, and staff watch for any reactions.

Preparation and What to Expect

General preparation and safety points that facilities commonly address include:

  • Screening questions about prior reactions to contrast, allergies, asthma, kidney disease, and pregnancy or breastfeeding.
  • A kidney function blood test may be requested for some people, such as those with known kidney disease.
  • Common mild effects include headache, nausea, a metallic taste, or a cool feeling at the injection site, which usually pass quickly.
  • Allergic-type reactions such as hives or itching are uncommon, and severe reactions are rare; imaging staff are trained to respond.
  • The FDA requires patients receiving a GBCA to be given a Medication Guide describing gadolinium retention.
  • Gadolinium contrast is generally avoided during pregnancy unless clinicians decide the benefit is important.

When Results Are Discussed With a Clinician

Topics commonly discussed with a clinician about contrast MRI include:

  • Why contrast is or is not recommended for a particular exam.
  • Which type of agent will be used and why.
  • How prior contrast exams or repeated scans are considered.
  • What a finding described as "enhancing" means in the person's overall situation.
  • Any symptoms after the scan, such as a delayed rash; difficulty breathing or swelling of the face or throat is generally treated as a medical emergency, and in the US people are advised to call 911.

Questions to Ask a Healthcare Professional

General questions people often find useful to bring to an appointment:

  • Why does this MRI need contrast?
  • Which contrast agent will be used, and is it a macrocyclic agent?
  • Is a kidney function test needed beforehand?
  • What should be reported to staff after the injection?
  • How is gadolinium retention considered when someone needs repeated scans?
  • Are there alternatives if contrast is not a good option?

Sources

This guide was written in plain language from the following authoritative references.

  1. FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings — U.S. Food and Drug Administration (FDA)
  2. Contrast Materials — RadiologyInfo.org (RSNA and ACR)
  3. MRI Safety — RadiologyInfo.org (RSNA and ACR)

Last updated October 8, 2026. FreeDoc guides are general educational information and are not a substitute for care from a qualified professional.